Circle Pharma and Verismo feature in coveted sessions.
ApexOnco Front Page
Recent articles
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
A more comprehensive dataset on JANX007 sends the group’s stock down.
The agency approved eight oncology products over the month.
Car-T therapies and ADCs feature among recent first-in-human study entrants.
The pivotal Harmoni-GI3 study has started enrolling patients.
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
Varegacestat’s pivotal study reads out imminently.
